Cytek Biosciences reported a decrease in total revenue for the first quarter of 2025 compared to the same period last year, primarily due to a slowdown in product sales in the US and EMEA. Despite this, the company saw strength in the APAC region and double-digit revenue growth in cell sorters and service businesses. Net loss increased compared to the prior year.
Total revenue for Q1 2025 was $41.5 million, a 7.6% decrease year-over-year.
Gross profit for Q1 2025 was $20.2 million, a 12% decrease year-over-year.
Net loss for Q1 2025 was $11.4 million, compared to a net loss of $6.2 million in Q1 2024.
Cash and marketable securities were $265.6 million as of March 31, 2025.
Cytek Biosciences revises its full year 2025 revenue guidance.
Analyze how earnings announcements historically affect stock price performance